AU2014321711B2 - Methods and materials for treating diabetes or liver steatosis - Google Patents

Methods and materials for treating diabetes or liver steatosis Download PDF

Info

Publication number
AU2014321711B2
AU2014321711B2 AU2014321711A AU2014321711A AU2014321711B2 AU 2014321711 B2 AU2014321711 B2 AU 2014321711B2 AU 2014321711 A AU2014321711 A AU 2014321711A AU 2014321711 A AU2014321711 A AU 2014321711A AU 2014321711 B2 AU2014321711 B2 AU 2014321711B2
Authority
AU
Australia
Prior art keywords
potato polysaccharide
polypeptide
polysaccharide preparation
potato
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014321711A
Other languages
English (en)
Other versions
AU2014321711A1 (en
Inventor
Richard Kream
Kirk J. Mantione
George B. Stefano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of AU2014321711A1 publication Critical patent/AU2014321711A1/en
Application granted granted Critical
Publication of AU2014321711B2 publication Critical patent/AU2014321711B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2014321711A 2013-09-19 2014-08-29 Methods and materials for treating diabetes or liver steatosis Ceased AU2014321711B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361879992P 2013-09-19 2013-09-19
US61/879,992 2013-09-19
PCT/US2014/053443 WO2015041837A1 (en) 2013-09-19 2014-08-29 Methods and materials for treating diabetes or liver steatosis

Publications (2)

Publication Number Publication Date
AU2014321711A1 AU2014321711A1 (en) 2016-05-12
AU2014321711B2 true AU2014321711B2 (en) 2019-11-14

Family

ID=52689269

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014321711A Ceased AU2014321711B2 (en) 2013-09-19 2014-08-29 Methods and materials for treating diabetes or liver steatosis

Country Status (6)

Country Link
US (2) US11160825B2 (enExample)
EP (1) EP3046566B1 (enExample)
JP (1) JP6535013B2 (enExample)
AU (1) AU2014321711B2 (enExample)
CA (1) CA2924597A1 (enExample)
WO (1) WO2015041837A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2016160590A1 (en) * 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for treating cancer
WO2018052849A1 (en) 2016-09-19 2018-03-22 Mitogenetics, Llc Materials and methods for producing and using mitochondrial preparations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040316A1 (en) * 2011-09-16 2013-03-21 Galectin Therapeutics, Inc. Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2134714A (en) 1936-11-25 1938-11-01 Jacob A Glassman Saccharine-aspirin tablet
US3622677A (en) 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
JP2001511153A (ja) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US20030159178A1 (en) 2000-02-10 2003-08-21 Peter Ulvskov Method for remodelling cell wall polysaccharide structures in plants
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
DE10045059A1 (de) * 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
WO2002032905A1 (en) 2000-10-20 2002-04-25 Ajinomoto Co.,Inc. Medicinal compositions, dose and method for treating malaria
US7098239B2 (en) 2001-06-20 2006-08-29 Merck & Co., Inc Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0117767D0 (en) 2001-07-20 2001-09-12 Unilever Plc Polymers and their synthesis
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
US20050214413A1 (en) 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
JP3998695B2 (ja) * 2005-04-22 2007-10-31 株式会社シクロケム αリポ酸水溶液及びその製造方法
WO2006114019A1 (en) 2005-04-26 2006-11-02 Versitech Limited Polysaccharide extract from lycium barbarum as neuroprotective agent against beta-amyloid peptide neurotoxicity
US7560536B2 (en) 2005-05-18 2009-07-14 Virginia Tech Intellectual Properties, Inc. Morning glory-derived anticancer agents, and novel ipomoeassin compounds
JP4863204B2 (ja) * 2005-06-15 2012-01-25 独立行政法人産業技術総合研究所 腎症関連疾患の診断方法及び診断キット
KR20070016520A (ko) * 2005-08-04 2007-02-08 박옥순 황기청국장분말을 이용한 건강식품
JP5247012B2 (ja) * 2006-07-25 2013-07-24 雪印メグミルク株式会社 脂肪肝抑制剤
NZ577427A (en) * 2007-01-18 2011-09-30 Novozymes As Method for producing potato products using debranching enzymes pullulanase and isoamylase
JP2009007309A (ja) * 2007-06-29 2009-01-15 Riken Vitamin Co Ltd α−リポ酸含有多芯型マイクロカプセル
KR101121543B1 (ko) 2007-07-04 2012-03-06 학교법인 선목학원 벼과식물로부터 수득되는 전분 또는 식이섬유를 포함하는허혈성 질환 및 퇴행성 뇌질환의 예방 및 치료를 위한조성물
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
JP2013506427A (ja) 2009-10-02 2013-02-28 ユニバーシティ オブ アイダホ 強化した難消化性デンプン含有量および抑制された血糖上昇応答を有するジャガイモ製品ならびにその方法
KR101093413B1 (ko) 2009-10-05 2011-12-14 고려대학교 산학협력단 뇌 신경 세포 보호 활성을 갖는 고구마 추출물 및 그의 용도
CN102762597A (zh) * 2009-12-11 2012-10-31 联合利华公众股份有限公司 适合调节免疫应答的多糖
WO2012016050A2 (en) 2010-07-28 2012-02-02 The General Hospital Corporation Chemoradiotherapy for kras-mutant colorectal cancer
JP2012149004A (ja) 2011-01-18 2012-08-09 Theravalues Corp 核内受容体の賦活剤
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013148282A1 (en) * 2012-03-28 2013-10-03 The Research Foundation Of State University Of New York Methods and materials related to nutritional supplement compositions containing a potato polysaccharide preparation
US9814255B2 (en) 2012-05-20 2017-11-14 Darco Natural Products Inc. Method for producing purple sweet potato juice and dried powder
US9180212B2 (en) 2012-05-22 2015-11-10 The Regents Of The University Of California β-amyloid plaque imaging agents
EP2902499B1 (en) 2012-09-28 2018-09-12 BNA Inc. Bna clamp method
CN103110657A (zh) 2013-01-31 2013-05-22 黄仁彬 玉郎伞多糖在制备药物中的应用
EP3008212A4 (en) 2013-06-10 2017-05-24 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2016160590A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for treating cancer
WO2017160678A1 (en) 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040316A1 (en) * 2011-09-16 2013-03-21 Galectin Therapeutics, Inc. Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease

Also Published As

Publication number Publication date
EP3046566B1 (en) 2020-12-02
US20160243152A1 (en) 2016-08-25
US20220110965A1 (en) 2022-04-14
CA2924597A1 (en) 2015-03-26
JP6535013B2 (ja) 2019-06-26
EP3046566A1 (en) 2016-07-27
WO2015041837A1 (en) 2015-03-26
EP3046566A4 (en) 2017-03-22
US11160825B2 (en) 2021-11-02
AU2014321711A1 (en) 2016-05-12
JP2016535762A (ja) 2016-11-17

Similar Documents

Publication Publication Date Title
Puchalska et al. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics
US20220110965A1 (en) Methods and materials for treating diabetes or liver steatosis
JP2021004266A (ja) ポテト多糖調製物を含有する栄養補助組成物に関連する方法および物質
Nepali et al. Triticum aestivum sprout-derived polysaccharide exerts hepatoprotective effects against ethanol-induced liver damage by enhancing the antioxidant system in mice
Evans et al. Effective treatments for insulin resistance: trim the fat and douse the fire
US20200268787A1 (en) Methods and materials for reducing amyloid beta levels within a mammal
US20190076461A1 (en) Materials and methods for treating hypoxic conditions
Vásquez-Reyes et al. The Effects of Novel Co-Amorphous Naringenin and Fisetin Compounds on a Diet-Induced Obesity Murine Model
SAPUTRI et al. Chlorogenic acid ameliorates memory dysfunction via attenuating frontal lobe oxidative stress and apoptosis in diabetic rat model
KR100390766B1 (ko) 필발로부터 얻은 지방산 생합성 효소 저해용 활성분획조성물
Dastyar et al. Cardiovascular property of resistance training with an emphasis on PI3K/AKT1 genes expression in type 2 diabetic rats
Al-Saadi et al. Evaluated the Up–regulation in Gene‎ Expression of Hepatic Insulin Gene and‎ Hepatic Insulin Receptor Gene in Type 1‎ Diabetic Rats Treated with Cuscuta chinesis‎ Lam.‎
Jing-wen et al. The anti-diabetic effect and possible mechanism of the Annona muricata L. root extract in type 2 diabetic mice.
Zhang et al. Timing of glucose intake drives distinct hepatic outcomes: Divergent glucose and lipid metabolism
US20190151357A1 (en) Materials and methods for producing and using mitochondrial preparations
Chari Central Nervous System (CNS) Nutrient Sensing in Diabetes
Yaw HuiPing et al. Lipoprotein lipase expression, serum triacylglycerol and tissue lipid deposition in rats fed on switching type of diet and treated with glycyrrhizic acid.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired